Russell Investments Group Ltd. Has $59,000 Stock Holdings in Kodiak Sciences Inc. $KOD

Russell Investments Group Ltd. grew its holdings in Kodiak Sciences Inc. (NASDAQ:KOD) by 729.9% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 21,039 shares of the company’s stock after buying an additional 18,504 shares during the quarter. Russell Investments Group Ltd.’s holdings in Kodiak Sciences were worth $59,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. US Bancorp DE increased its stake in shares of Kodiak Sciences by 131.7% in the first quarter. US Bancorp DE now owns 9,282 shares of the company’s stock valued at $26,000 after buying an additional 5,276 shares in the last quarter. Vontobel Holding Ltd. acquired a new stake in shares of Kodiak Sciences in the first quarter valued at approximately $28,000. Public Employees Retirement System of Ohio increased its holdings in shares of Kodiak Sciences by 183.9% in the fourth quarter. Public Employees Retirement System of Ohio now owns 14,759 shares of the company’s stock valued at $147,000 after purchasing an additional 9,560 shares in the last quarter. MetLife Investment Management LLC acquired a new stake in shares of Kodiak Sciences in the fourth quarter valued at approximately $209,000. Finally, Aries Wealth Management acquired a new stake in shares of Kodiak Sciences in the first quarter valued at approximately $70,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. HC Wainwright raised their price target on shares of Kodiak Sciences from $3.00 to $5.00 and gave the company a “neutral” rating in a report on Monday, August 18th. Barclays raised their price target on shares of Kodiak Sciences from $4.00 to $7.00 and gave the company an “underweight” rating in a report on Thursday, August 14th. Finally, JPMorgan Chase & Co. raised shares of Kodiak Sciences from an “underweight” rating to a “neutral” rating and set a $15.00 price target for the company in a report on Thursday, August 14th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Kodiak Sciences currently has an average rating of “Hold” and an average target price of $11.75.

Kodiak Sciences Stock Performance

Shares of KOD stock opened at $8.55 on Friday. Kodiak Sciences Inc. has a 52-week low of $1.92 and a 52-week high of $11.60. The stock has a market cap of $451.61 million, a PE ratio of -2.25 and a beta of 2.45. The firm’s 50 day moving average price is $7.15 and its two-hundred day moving average price is $4.80.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.02). As a group, sell-side analysts predict that Kodiak Sciences Inc. will post -3.45 earnings per share for the current fiscal year.

Kodiak Sciences Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.